Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 8/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 8/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.46 |
| ▸ | CHRNG | P07510 | 7/20 | 0.46 |
| ▸ | CHRND | Q07001 | 7/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16770967 | 0.70 | SLC6A2 (0.41) | SLC6A2SLC6A3CHRNA1CHRNB1CHRNB2 | |
| SCHEMBL30802 | 0.68 | CYP2A6 (0.40) | TSHR | |
| SCHEMBL9023919 | 0.66 | CHRNB2 (0.33) | SLC6A2SLC6A3CHRNA1CHRNB1CHRNB2 | |
| SCHEMBL18288060 | 0.64 | MAOA (0.46) | SLC6A2SLC6A3SLC6A4TSHR | |
| SCHEMBL28198518 | 0.64 | CCR2 (0.42) | SLC6A2SLC6A3CHRNA1CHRNB1CHRNB2 | |
| SCHEMBL18288013 | 0.63 | AHR (0.39) | SLC6A2SLC6A3CHRNA1CHRNB1CHRNB2 | |
| SCHEMBL901820 | 0.62 | CHRNA1 (0.36) | SLC6A2SLC6A3CHRNA1CHRNB1CHRNB2 | |
| SCHEMBL18722078 | 0.62 | — | — | |
| SCHEMBL9541960 | 0.61 | CHRNA1 (0.35) | SLC6A2SLC6A3CHRNA1CHRNB1CHRNB2 | |
| SCHEMBL16758861 | 0.61 | WDR91 (0.41) | SLC6A2SLC6A3CHRNA1CHRNB1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115135639-B | Efficient process for preparing 6-carboxybenzoxazole derivatives | 辉瑞爱尔兰制药公司 | 2025-04-01 | — | — | CN | claimed |
| EP-4077287-A1 | EFFICIENT PROCESS FOR MAKING 6-CARBOXY BENZOXAZOLE DERIVATIVES | Pfizer Ireland Pharmaceuticals (IE) | 2022-10-26 | — | — | EP | claimed |
| CN-115135639-A | Efficient process for preparing 6-carboxybenzoxazole derivatives | 辉瑞爱尔兰制药公司 | 2022-09-30 | — | — | CN | claimed |
| WO-2021124158-A1 | EFFICIENT PROCESS FOR MAKING 6-CARBOXY BENZOXAZOLE DERIVATIVES | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-06-24 | — | — | WO | claimed |
| EP-4077287-B1 | EFFICIENT PROCESS FOR MAKING 6-CARBOXY BENZOXAZOLE DERIVATIVES | PFIZER IRELAND PHARMACEUTICALS UNLIMITED COMPANY (IE) | 2025-11-19 | — | — | EP | disclosed |
| CN-115135639-B | Efficient process for preparing 6-carboxybenzoxazole derivatives | 辉瑞爱尔兰制药公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20230090609-A1 | Efficient Process For Making 6-Carboxy Benzoxazole Derivatives | PFIZER IRELAND PHARMACEUTICALS (US) | 2023-03-23 | — | — | US | disclosed |
| EP-4077287-A1 | EFFICIENT PROCESS FOR MAKING 6-CARBOXY BENZOXAZOLE DERIVATIVES | Pfizer Ireland Pharmaceuticals (IE) | 2022-10-26 | — | — | EP | disclosed |
| CN-115135639-A | Efficient process for preparing 6-carboxybenzoxazole derivatives | 辉瑞爱尔兰制药公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2021124158-A1 | EFFICIENT PROCESS FOR MAKING 6-CARBOXY BENZOXAZOLE DERIVATIVES | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021124158-A1 | EFFICIENT PROCESS FOR MAKING 6-CARBOXY BENZOXAZOLE DERIVATIVES | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230090609-A1 | Efficient Process For Making 6-Carboxy Benzoxazole Derivatives | CYP2B6, CYP4X1, CYP2C9 | SLC6A2 3173/4885SLC6A3 2658/4885CHRNA1 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.